Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Calorie

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43892   clinical trials with a EudraCT protocol, of which   7299   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Calorie. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-000530-54 Sponsor Protocol Number: VS56151/17000277 Start Date*: 2018-01-16
    Sponsor Name:University of Copenhagen
    Full Title: The effect of cannibinols in patients with pancreatic cancer in the palliative state
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10037027 Protein-calorie malnutrition LLT
    20.0 100000004861 10064015 Cancer cachexia LLT
    20.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003696-18 Sponsor Protocol Number: uni-koeln-1547 Start Date*: 2013-07-25
    Sponsor Name:University of Cologne
    Full Title: Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk.
    Medical condition: contrast-induced nephropathy, acute renal failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003473-34 Sponsor Protocol Number: NN9536-4376 Start Date*: 2018-05-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) PT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003726-32 Sponsor Protocol Number: NN9536-4378 Start Date*: 2018-08-22
    Sponsor Name:Novo Nordisk A/S
    Full Title: Two-year effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
    Medical condition: Obesity Overweight
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005585-32 Sponsor Protocol Number: 111111733104 Start Date*: 2016-06-24
    Sponsor Name:Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen
    Full Title: Synergy effect of the appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight loss and health after a low calorie diet - the S-LiTE randomized trial
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000204-11 Sponsor Protocol Number: NN9536-4578 Start Date*: 2021-01-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of subcutaneous semaglutide 2.4 mg once-weekly compared to placebo in subjects with obesity and knee osteoarthritis
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) SE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005427-32 Sponsor Protocol Number: MeMeMe Start Date*: 2014-08-18
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Randomized controlled trial of metformin and dietary restriction to prevent age-related morbid events in people with metabolic syndrome
    Medical condition: metabolic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003436-36 Sponsor Protocol Number: NN9536-4373 Start Date*: 2018-05-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) DK (Completed) BG (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002953-11 Sponsor Protocol Number: NN9932-4737 Start Date*: 2021-06-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity
    Medical condition: Obesity Overweight
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-002968-10 Sponsor Protocol Number: 024 Start Date*: 2008-01-17
    Sponsor Name:Department of Medicine I, Clinical Dep. f. Oncology, University Hospital,
    Full Title: Treatment of Patients Suffering from Tumour Cachexia with Dronabinol (tetrahydrocannabinol) or Placebo Comparison of individually optimised dosages in a double blind, randomised parallel design
    Medical condition: tumour cachexia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006534-40 Sponsor Protocol Number: NN9932-4954 Start Date*: 2022-09-21
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide 25 mg once daily in adults with overweight or obesity (OASIS 4)
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003414-10 Sponsor Protocol Number: NN9536-4374 Start Date*: 2018-05-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes
    Medical condition: 1. Obesity 2. Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002431-18 Sponsor Protocol Number: NN9536-4451 Start Date*: 2019-09-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity
    Medical condition: Overweight Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) IE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000790-94 Sponsor Protocol Number: NN9536-4999 Start Date*: 2022-11-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity.
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) PT (Ongoing) NO (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002813-24 Sponsor Protocol Number: BAY94-8862/16538 Start Date*: 2016-11-15
    Sponsor Name:Bayer AG
    Full Title: Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of a single oral dose of finerenone 20 mg as suspension (pediatric formulation), intact tablet and crushe...
    Medical condition: Diabetic kidney disease
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002895-29 Sponsor Protocol Number: BAY94-8862/18290 Start Date*: 2016-10-28
    Sponsor Name:Bayer AG
    Full Title: Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of single oral doses of finerenone 1.25 mg and 5 x 0.25 mg oro-dispersible tablet (pediatric formulatio...
    Medical condition: Treatment of diabetic kidney disease (adults) and chronic kidney disease (children).
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001945-14 Sponsor Protocol Number: NN9838-4433 Start Date*: 2019-01-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of safety and efficacy of NNC0174-0833 for weight management – a dose finding trial
    Medical condition: Obesity Overweight
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005619-33 Sponsor Protocol Number: NN8022-4272 Start Date*: 2016-12-14
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002944-26 Sponsor Protocol Number: DDD19DASA Start Date*: 2020-01-24
    Sponsor Name:KU Leuven Drug Delivery & Disposition
    Full Title: Exploring the gastrointestinal behavior of dasatinib in healthy volunteers
    Medical condition: Healthy human male volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002235-60 Sponsor Protocol Number: NN9536-7545 Start Date*: 2023-02-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 29 16:18:49 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA